Roche (RHHBY) announced that the FDA has approved a label expansion of its lung cancer drug, Alecensa. The drug is now approved for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node-positive), as detected by an FDA-approved test. Alecensa is a kinase inhibitor, already approved as the first and second-line treatment for ALK-positive metastatic NSCLC, in various countries like the United States, E ...